The life sciences industry has spent decades scaling scientific innovation, yet regulatory operations remain constrained by a model built for a paper-based era. For most biopharmaceutical companies, regulatory submissions follow a slow, sequential pattern known as the wave model. A change is approved in one country, then cascades market by market, often taking years to finally reach global approval. Each step depends on the one before it, locking sponsors and regulators into an outdated, linear process.
This isn’t just an efficiency issue.
What was once accepted as inevitable is now becoming a competitive and access-limiting constraint. The wave model has become an increasingly costly operating structure that:
- Drives drug lag
- Inflates regulatory burden
- Compresses patent value
- Erodes lifetime revenue
Most critically, it delays patient access by months or even years despite the science being ready.
The critical vantage point
At Accumulus Technologies we work at the intersection of life sciences organizations and national regulatory authorities (NRAs) to enable real-time regulatory collaboration. This vantage point affords us a front-row view into what’s driving delays – and what’s changing fast.
One shift is unmistakable: the era of waiting in line is ending.
In 2026, we believe the industry will cross a tipping point: organizations will shift from managing sequential regulatory execution to optimizing global regulatory performance through parallel, coordinated engagement.
For a deeper look at why we believe the era of waiting in line is over and our predictions for what comes next, download our latest industry perspective.